利伐沙班在外周动脉疾病患者中的疗效与安全性:GRADE 评估的系统评价与荟萃分析
该系统评价与荟萃分析纳入 6 项研究共 39991 例外周动脉疾病患者,比较利伐沙班(单用或联合阿司匹林)与对照的疗效与安全性。结果显示利伐沙班显著降低复合疗效终点、急性肢体缺血和血栓栓塞风险,但显著增加大出血风险;单用利伐沙班与截肢风险降低相关,而联合阿司匹林未显示截肢风险显著降低。
要点
- 利伐沙班降低复合疗效终点(RR 0.84)、急性肢体缺血(RR 0.65)和血栓栓塞(RR 0.60)。
- 利伐沙班增加大出血(HR 1.54)和 ISTH 定义出血(RR 1.45)风险。
- 单用利伐沙班与截肢风险降低相关(RR 0.50),联合阿司匹林未显示显著降低。
核心结论
- 利伐沙班为基础的治疗降低 PAD 患者试验定义的复合疗效终点、急性肢体缺血和血栓栓塞,但增加大出血风险。
- 结果支持在仔细选择的患者中个体化使用利伐沙班,平衡缺血与肢体保护获益及出血风险。
研究设计与样本
- 检索 PubMed、Cochrane 和 EMBASE 的随机对照试验和非随机比较研究。
- 比较利伐沙班(单用或联合阿司匹林)与安慰剂或标准抗血小板治疗。
- 共纳入 6 项研究、39991 例参与者,使用 R v4.5.1 随机效应模型合并 RR 和 HR(95%CI)。
- 按利伐沙班联合阿司匹林与利伐沙班单用进行亚组分析。
主要发现
- 与对照相比,利伐沙班显著降低复合疗效终点(RR=0.84,95%CI 0.78-0.91,P<0.001)。
- 利伐沙班显著降低急性肢体缺血(RR=0.65,95%CI 0.55-0.78,P<0.001)和血栓栓塞(RR=0.60,95%CI 0.38-0.97,P=0.037)。
- 利伐沙班联合阿司匹林未显示截肢风险显著降低,而利伐沙班单用显示显著降低(RR=0.50,95%CI 0.30-0.85,P=0.003)。
- 利伐沙班显著增加大出血(HR=1.54,95%CI 1.38-1.72,P<0.001)和 ISTH 定义出血(RR=1.45,95%CI 1.19-1.76,P<0.001)风险。
- 卒中、心肌梗死、主要不良肢体事件、致命性出血、死亡率或心血管死亡率无显著差异。
临床怎么用
- 在仔细选择的 PAD 患者中可考虑利伐沙班为基础的治疗,以降低缺血和肢体事件风险。
- 使用利伐沙班时需权衡大出血风险,个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peripheral artery disease (PAD) is a common atherosclerotic disorder characterized by progressive arterial narrowing in the limbs. This study aims to determine the efficacy and safety of rivaroxaban, focusing on major cardiovascular events, limb outcomes, and bleeding risks. METHODS: PubMed, Cochrane, and EMBASE were searched for randomized controlled trials (RCTs) and nonrandomized comparative studies that compared rivaroxaban, either alone or in combination with aspirin, to placebo or standard care such as antiplatelet therapy. Risk ratios and hazard ratios with 95% confidence intervals were pooled using R v4.5.1 with an appropriate random-effects model applied. Subgroup analyses were performed according to rivaroxaban plus aspirin versus rivaroxaban alone. RESULTS: A total of 39,991 participants across 6 studies were included. Compared with control, use of rivaroxaban was linked to a significant reduction in composite efficacy outcomes (relative risk [RR] = 0.84, 95% confidence interval [CI] 0.78-0.91, P < 0.001), risk of acute limb ischemia (RR = 0.65, 95% CI 0.55-0.78, P < 0.001), and thromboembolism (RR = 0.60, 95% CI 0.38-0.97, P = 0.037). Although rivaroxaban plus aspirin failed to show a significant reduction in the risk of amputation, rivaroxaban alone reported a significant risk reduction (RR = 0.50, 95% CI 0.30-0.85, P = 0.003). However, its use was associated with a significantly higher risk of major bleeding (hazard ratio [HR] = 1.54, 95% CI 1.38-1.72, P < 0.001) and International Society on Thrombosis and Hemostasis-defined bleeding (RR = 1.45, 95% CI 1.19-1.76, P < 0.001). No significant differences were observed for stroke, myocardial infarction, major adverse limb events, fatal bleeding, mortality, or cardiovascular mortality. CONCLUSION: Rivaroxaban-based therapy reduced the trial-defined composite efficacy outcome, acute limb ischemia, and thromboembolism in patients with PAD, but increased the risk of major bleeding. These findings support individualized use of rivaroxaban-based therapy in carefully selected patients, balancing ischemic and limb-protective benefits against bleeding risk.
引用
- Shahzaib M, Roshaan M, Buhadur Ali MK, et al. Efficacy and Safety of Rivaroxaban in Patients with Peripheral Artery Disease: A GRADE-assessed Systematic Review and Meta-Analysis. Ann Vasc Surg. 2026. PMID: 42448029. doi:10.1016/j.avsg.2026.06.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。